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Introduction: The aim of this study was to radiologically identify 
early lung adenocarcinoma in clinical T1bN0M0 lung cancer, based 
on pathological findings and long-term prognosis.
Methods: In this study, we reviewed lung nodules findings on thin-
section computed tomography in 173 patients with clinical T1bN0M0 
lung adenocarcinoma who underwent surgery between 2003 and 2007. 
The ratio of the size of solid attenuation to the maximum tumor dimen-
sion (consolidation/tumor [C/T] ratio) was calculated. We defined two 
groups of patients by C/T ratio cutoff levels of 0.00, 0.25, 0.50, 0.75, 
and 1.00 and compared the rates of pathological nonaggressive lung 
adenocarcinoma, overall survival, and recurrence rates between the 
groups. The percentages of predominant histological subtypes were 
compared between two groups divided by the optimal cutoff level. 
Various clinical factors were analyzed by univariate and multivariate 
analyses to predict pathological lymph node involvement.
Results: The median follow-up period was 62 months. All patients 
with C/T ratios of 0.5 or less were diagnosed as having pathological 
nonaggressive adenocarcinomas, and there was no recurrence; their 
5-year overall survival rate was 97.4%, which was significantly bet-
ter than that for patients with C/T ratios of greater than 0.5 (76.2%). 
None of the ground-glass opacity–predominant tumors were pre-
dominantly solid adenocarcinoma with mucin. The C/T ratio of 0.5 
or more was an independent predictor of lymph node involvement.
Conclusion: In patients with clinical T1bN0M0 disease, the C/T 
ratio of 0.5 or less identified early lung adenocarcinoma. In patients 
with the identified early disease, a feasibility study of limited surgery 
may be warranted.
Key Words: Early lung cancer, Ground-glass opacity, Non–small-
cell lung cancer, Limited surgery.
(J Thorac Oncol. 2013;8: 1289–1294)
Remarkable improvement in spatial resolution of computed tomography (CT) has provided new tools for lung cancer 
diagnosis. Thin-section CT (TSCT) findings of lung cancer 
have been extensively analyzed. Various measures to predict 
less-invasive lung cancers have been reported, for example, 
classically used tumor size, tumor shadow disappearance 
rate,1,2 visual estimation of the consolidation component,3–5 
size of the solid component, maximum standardized uptake 
value by 18F-fluorodeoxyglucose positron emission tomog-
raphy/CT,6 and the ratio of the size of solid attenuation to 
the maximum tumor dimension (consolidation/tumor [C/T] 
ratio).7 Suzuki et al.8 reported a multi-institutional prospec-
tive radiological study for early lung cancer (Japan Clinical 
Oncology Group: JCOG trial 0201) in 2011 and concluded 
that the C/T ratio was the most reliable measure for identifica-
tion of nonaggressive lung cancer on TSCT, compared with 
the visual estimation and tumor shadow disappearance rate 
methods. On the basis of these results, two pivotal prospec-
tive studies on limited resection for small peripheral lung can-
cer assessed by C/T ratios were initiated in Japan (JCOG trial 
0802/West Japan Oncology Group trial 4607L and JCOG trial 
0804).9 In addition, there is an ongoing, prospective, random-
ized controlled trial (lobectomy versus sublobar resection) for 
small (≤2 cm) peripheral stage IA non–small-cell lung can-
cer in the United States of America and Canada (Cancer and 
Leukemia Group B trial 14053). However, there are no pro-
spective, limited resection trials for clinical T1b (cT1b) early 
lung cancer. The aim of this study was to radiologically iden-
tify early lung adenocarcinoma in patients with cT1bN0M0 
lung cancer, based on pathological findings and long-term 
outcomes.
PATIENTS AND METHODS
Patient Selection
Between January 2003 and December 2007, 1000 non-
small cell lung cancer patients underwent complete resection 
by lobectomy or pneumonectomy with systematic lymph node 
dissection. Basically, regional lymph nodes were dissected 
in our hospital according to the previous article by Naruke 
et al.10 Of these, 210 patients (21.0%) had lung adenocar-
cinoma of cT1bN0M0 according to the 7th edition of the 
tumor–node–metastasis (TNM) classification.11 We excluded 
patients with multiple primary lung cancers, extensive cav-
ity formation, or massive occlusive pneumonia on preopera-
tive TSCT as well as those who underwent induction therapy 
or whose clinical course records were incomplete. Thus, we 
included 173 patients (17.3%) whose preoperative TSCT data 
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were available for review in this study. Data collection and 
analyses were approved, and the need to obtain informed con-
sent from each patient was waived by the institutional review 
board in February 2013.
Radiological Evaluation by TSCT
Contrast-enhanced CT scans at 5 to 10 mm collima-
tion of the chest and upper abdomen were used to assess the 
clinical staging of all patients with cT1N0M0 lung cancer. In 
addition, TSCT images at 1 to 2 mm collimation were used 
to evaluate primary lesions. The X-vigor CT system (Toshiba 
Medical Systems, Tokyo, Japan) was used to perform the CT 
scans. CT images were evaluated on a monitor display with a 
window level of −600 HU and a window width of 1800 HU. 
Two observers (KA and TH), who were unaware of the patho-
logical findings and prognosis, reviewed each lung nodule on 
preoperative TSCT scans. Tumor diameter was measured at 
the longest dimension of a tumor. The C/T ratio was calcu-
lated in one dimension on TSCT (Supplemental Figure). The 
consolidation component was defined as an area of increased 
opacification that completely obscured the underlying vas-
cular structures. Ground-glass opacity (GGO) was defined 
as increased hazy density in an area without obscuring the 
underlying vascular structure.8 Discrepancies in interpretation 
between observers were resolved by consensus. We set C/T 
ratio cutoff levels at 0.0, 0.25, 0.5, 0.75, and 1.0. A C/T ratio 
of 0.0 represented pure GGO nodules, and the C/T ratio of 1.0 
represented solid nodules without GGO components. Disease 
stage during the study period was determined according to the 
6th edition of the TNM classification,12 but for this report we 
reclassified this study population according to the 7th edition 
of the TNM classification.11
Pathological Evaluation
Surgical specimens were fixed with 10% formalin and 
embedded in paraffin. Serial 4-μm sections were stained with 
hematoxylin and eosin and by the Alcian blue–periodic acid–
Schiff method for cytoplasmic mucin production. We used 
elastica van Gieson or Victoria blue–van Gieson staining to 
visualize elastic fibers and evaluate vascular and pleural inva-
sion. Lymphatic permeation was diagnosed with the help of 
D2-40 staining. Histological type was determined according 
to the World Health Organization classification of cell types.13
Patient Follow-Up
Patients were evaluated at 3-month intervals for the 
first 2 years and typically at 6-month intervals thereafter on 
an outpatient basis. The follow-up evaluation included phys-
ical examination, chest radiography, and blood examination 
including pertinent tumor markers. Whenever any symptoms 
or signs of recurrence were detected, further evaluations 
were conducted, including CT scan of the chest and abdo-
men, brain magnetic resonance imaging, and bone scintig-
raphy. After 2004, integrated positron emission tomography/
CT was also performed when appropriate. Annual follow-up 
CT examination was also used for lung cancer patients who 
had undergone complete resection in the absence of some 
symptoms or abnormal examination findings. Recurrence 
was diagnosed on the basis of compatible physical examina-
tion and diagnostic imaging findings, and the diagnosis was 
histologically confirmed when clinically feasible. The length 
of overall survival was defined as the interval in months 
between the date of surgical intervention and the last follow-
up date or death resulting from any cause. Observations were 
censored at the last follow-up when the patient was alive or 
lost to follow-up. The date of recurrence was defined as the 
date of histological proof or, in cases diagnosed on the basis 
of clinicoradiological findings, the date of identification by 
a physician.
Pathological and Prognostic Analyses
We defined pathological nonaggressive lung adenocar-
cinoma as lung adenocarcinoma without nodal involvement, 
vascular invasion, lymphatic permeation, and pleural inva-
sion, and its rates, overall survival, and recurrence rates were 
compared between each group defined by the C/T ratio cutoff 
levels. On the basis of the pathological findings and prognoses, 
we determined the optimal cutoff C/T ratio that best discrimi-
nated early lung adenocarcinoma. The predominant histologi-
cal subtype (bronchioloalveolar carcinoma [BAC], papillary 
adenocarcinoma, acinar adenocarcinoma, and solid adenocar-
cinoma with mucin) of each tumor was determined, and the 
percentages of these subtypes were calculated for the groups 
divided by the optimal C/T ratio cutoff level. Various clini-
cal factors (C/T ratio, sex, age, smoking history, preoperative 
serum carcinoembryonic antigen level, laterality, tumor origin 
lobe, and maximum tumor diameter) were used for univariate 
and multivariate analyses to predict pathological lymph node 
involvement.
Statistical Analysis
All cumulative overall survival rates were estimated by 
the Kaplan–Meier method. Comparisons between groups were 
calculated by the log-rank test. We used Fisher’s exact test for 
univariate analysis as well as multivariate logistic regression 
analysis to identify pathological lymph node involvement pre-
dictors. All statistical analyses were performed using JMP 10 
statistical software (Version 10.0.2. 64-bit edition; SAS Institute 
Inc., Cary, NC) and GraphPad Prism (Prism for Windows, 
Version 5.02; GraphPad Software, Inc., La Jolla, CA).
RESULTS
Patient clinical and pathological characteristics are 
summarized in Table 1. The median follow-up period was 
62 months (range, 3–108 months). The average ± SD of the 
tumor diameter was 25 ± 2.8 mm. There were only five patients 
(2.9%) with pure GGO tumor (C/T ratio = 0.0) and 69 patients 
(39.9%) with completely solid tumor (C/T ratio = 1.0). There 
were no significant correlations between the maximum tumor 
diameter and C/T ratio (r = 0.16, Spearman’s rank correlation 
coefficient). Lymph node metastasis was pathologically con-
firmed in 19 patients (10.9%).
There were 109 patients (63.0%) with pathological non-
aggressive lung adenocarcinoma (defined as lung adenocarci-
noma without nodal involvement, vascular invasion, lymphatic 
permeation, and pleural invasion). All patients with C/T ratios 
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of 0.5 or less had pathological nonaggressive cancers (Table 2). 
Of the 69 pure solid tumors (C/T ratio = 1.0), 38 (55%) were 
pathologically diagnosed as invasive adenocarcinoma (having 
any of the following pathological findings: nodal involvement, 
vascular invasion, lymphatic permeation, or pleural invasion). 
When C/T ratio cutoff levels were set at 0.50, 0.75, and 1.00, 
overall survival was significantly better in the lower C/T ratio 
group than that in the higher C/T ratio group (Fig. 1). The 
5-year survival rate of patients with C/T ratios of 0.5 or less 
was 97.4%, which was significantly better compared with that 
of the patients with C/T ratios 0.5 or more (76.2%; Fig. 1C). 
During the follow-up period, 42 recurrences (22 locoregional 
only and 20 including distant sites) were observed (Table 3). 
Patients with C/T ratios of 0.5 or less did not develop recur-
rence, but one patient died of another cancer. In contrast, 31% 
patients (42 of 134) with C/T ratios 0.5 or more developed 
recurrences. On the basis of these results, we determined that 
a C/T ratio cutoff level of 0.5 was optimal for discrimination 
of early lung adenocarcinoma. Otherwise, seven patients (6%) 
among 109 patients who revealed pathological nonaggressive 
lung adenocarcinoma developed recurrence and 31 patients 
(48%) among 64 patients who revealed pathological invasive 
lung adenocarcinoma developed recurrence.
In more than half of the GGO-predominant tumors (C/T 
ratio ≤0.5), the predominant histological subtype was BAC 
(62%) followed by papillary adenocarcinoma (33%), whereas 
there were no tumors of predominantly solid adenocarcinoma 
with mucin. In contrast, of all consolidation-predominant 
tumors (C/T ratio >0.5), solid adenocarcinomas accounted for 
11% (16 of 152) and BAC for only 22% (33 of 152; Table 4). 
There was a significant difference in the distribution of pre-
dominant subtypes between GGO-predominant and consoli-
dation-predominant tumors (p < 0.01; Fisher’s exact test).
On the univariate analysis, the C/T ratio cutoff levels 
of 0.0, 0.25, and 1.0 were not significantly associated with 
pathological lymph node metastasis. On multivariate analysis, 
the C/T ratio cutoff level of 0.75 was an independent predic-
tor of node metastasis (odds ratio for C/T ratio >0.75, 3.4); 
however, a C/T ratio cutoff level of 0.5 was by far a stronger 
independent predictor (odds ratio for C/T ratio >0.5, >100; 
Table 5) than C/T ratio of 0.75.
DISCUSSION
Since 1995, lobectomy and lymph node dissection have 
been the standard therapy for stage IA lung cancer, because 
of the only randomized controlled trial reported by the Lung 
Cancer Study Group.14 However, the development of CT tech-
nology and the widespread use of TSCT have enabled earlier 
TABLE 1.  Patients Clinicopathological Characteristics
Patient Characteristics No. of Patients (%) (N = 173)
Age (yr)
  <70 111 (64.2)
  ≥70 62 (35.8)
Sex
  Male 75 (43.4)
  Female 98 (56.6)
Smoking history
  Never smoker 85 (49.4)
  Current/former smoker 88 (50.6)
Preoperative serum CEA levela
  ≤5.0 ng/ml 137 (79.2)
  >5.0 ng/ml 35 (20.2)
Tumor location
  Right upper lobe 62 (35.8)
  Right middle lobe 13 (7.5)
  Right lower lobe 32 (18.5)
  Left upper lobe 41 (23.7)
  Left lower lobe 25 (14.5)
Maximum tumor size (mm)
  Average ± SD 25 ± 2.8
C/T ratio
  0 (pure GGO) 5 (2.9)
  >0, ≤0.25 8 (4.6)
  >0.25, ≤0.5 26 (15.0)
  >0.5, ≤0.75 33 (19.1)
  >0.75, <1.0 32 (18.5)
  1 (solid tumor) 69 (39.9)
Pathological lymph node metastasis
  pN0 154 (89.0)
  pN1 9 (5.2)
  pN2 10 (5.7)
Lymphatic permeation
  Absent 147 (85.0)
  Present 26 (15.0)
Vascular invasion
  Absent 123 (71.1)
  Present 50 (28.9)
Pleural invasion
  Absent 138 (80.2)
  Present 34 (19.8)
aOne patient with missing value.
CEA, carcinoembryonic antigen; C/T ratio, consolidation/tumor ratio; GGO, 
ground-glass opacity.
TABLE 2.  Relationship between C/T Ratio and Pathological 
Invasiveness
C/T Ratio
Total No. of 
Patients
Pathological  
Nonaggressive 
Cancera
Pathological 
Invasive 
Cancera
0 (Pure GGO) 5 5 (100) 0 (0)
0 < C/T ratio ≤ 0.25 8 8 (100) 0 (0)
0.25 < C/T ratio ≤ 0.5 26 26 (100) 0 (0)
0.5 < C/T ratio ≤ 0.75 33 24 (73) 9 (27)
0.75 < C/T ratio < 1.0 32 15 (47) 17 (53)
1 (Pure solid) 69 31 (45) 38 (55)
Numbers in parentheses are percentages.
aDefined as absence of nodal involvement, pleural invasion, lymphatic permeation, 
and vascular invasion. If one or more of these findings were positive, tumors were 
classified as invasive cancer.
C/T ratio, consolidation/tumor ratio; GGO, ground-glass opacity.
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detection of primary lung cancers, particularly tumors with 
GGO components. Many retrospective studies3–5,7,15–18 have 
focused on identifying less-invasive lung cancers on the basis 
of preoperative TSCT findings along with the recognition 
of BAC and Noguchi’s classification.16,19 On the basis of the 
findings from these retrospective studies, two trials of limited 
resection for small peripheral lung cancer according to C/T 
ratios determined on preoperative TSCT were initiated for 
patients with T1a lung cancer in Japan.7,8,15,17 The results from 
these studies may change future surgical strategies for lung 
adenocarcinomas that are less than 2 cm in diameter.
In 2009, the TNM classification for primary lung can-
cer was revised, and T1 tumors were subcategorized as T1a 
(≤2.0 cm) and T1b (>2.0 cm and ≤3.0 cm) in the current 7th 
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FIGURE 1.  Overall survival compari-
son between two groups divided by 
C/T ratio. A, Cut-off level of C/T ratio 
at 0, (B) at 0.25, (C) at 0.5, (D) at 0.75, 
and (E) at 1.0. p was determined by 
the log-rank test. C/T, consolidation/
tumor.
TABLE 3.  Relationship between Relapse Site and C/T Ratio
C/T Ratio
Total No. of 
Patients
No  
Recurrence
Locoregional 
Site Only
Including 
Distant 
Site
0 (Pure GGO) 5 5 (100) 0 (0) 0 (0)
0 < C/T ratio ≤ 0.25 8 8 (100) 0 (0) 0 (0)
0.25 < C/T ratio ≤ 0.5 26 26 (100) 0 (0) 0 (0)
0.5 < C/T ratio ≤ 0.75 33 27 (82) 4 (12) 2 (6)
0.75 < C/T ratio < 1.0 32 21 (66) 7 (22) 4 (13)
1 (Pure solid) 69 44 (64) 11 (16) 14 (20)
Numbers in parentheses are percentages.
C/T ratio, consolidation/tumor ratio; GGO, ground-glass opacity.
TABLE 4.  Predominant Histological Subtype
C/T Ratio
C/T ≤0.5 (%)
n = 39
0.5 < C/T < 1.0 (%)
n = 83
C/T = 1.0 (%)
n = 69
Bronchioloalveolar 
carcinoma
21 (62) 16 (19) 17 (25)
Papillary 
adenocarcinoma
13 (33) 38 (46) 32 (46)
Acinar adenocarcinoma 2 (5) 22 (27) 11 (16)
Solid adenocarcinoma 
with mucin
0 (0) 7 (8) 9 (13)
C/T ratio, consolidation/tumor ratio.
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TNM classification. Because most researchers have targeted 
peripheral early lung adenocarcinomas of 2 cm or less in 
diameter, we focused on T1b tumors and examined the pos-
sibility of limited resection for this population.
Aoki et al.15 reported that patients who had tumors 
composed of less than 50% GGO showed significantly bet-
ter outcomes than patients who had tumors composed of less 
than 50% GGO. They also pointed out that 17 patients with 
adenocarcinomas (<2 cm) that were composed of less than 
50% GGO had no lymph node metastases or vessel invasion 
and developed no recurrence. However, the median follow-up 
period in that study was relatively short at 31 months, and the 
study did not separately examine cT1b patients.15
The present study showed that GGO-predominant 
tumors (C/T ratio ≤0.5) in patients with cT1b lung adenocar-
cinoma were nonaggressive adenocarcinomas, and no locore-
gional or distant metastases developed after lobectomy and 
lymph node dissection. Patients were observed for a minimum 
of 5 years. The result that no distant or lymph node metasta-
ses were observed in the GGO-predominant tumors strongly 
suggests that these tumors are localized. These results are 
compatible with those from a recent report on a prospective 
CT finding study in Japan to define nonaggressive adenocarci-
noma of the lung.20 These GGO-predominant tumors can most 
likely be cured by limited lung resection alone without lymph 
node dissection when an adequate margin is secured.
GGO components of lung tumors on TSCT histo-
logically correspond to lepidic growth patterns of cancer 
cells, and central consolidation typically corresponds to 
alveolar collapse and/or fibrotic foci.16,21 Kuriyama et al. 
reported that the measurement of the GGO area in a lung 
tumor was useful in differentiating localized BAC from 
invasive adenocarcinoma.21 It may be difficult to clearly 
determine histological subtypes of adenocarcinoma on the 
basis of TSCT findings, but we found that no cT1b GGO-
predominant (C/T ratio ≤0.5) lung adenocarcinomas were 
solid adenocarcinoma predominant. Solid adenocarcinoma 
with mucin is known to be highly aggressive, with frequent 
vessel invasion and lymph node metastases, and their sur-
gical outcome is significantly poorer than that for other 
subtypes.22 In consolidation-predominant (C/T ratio >0.5) 
tumors, solid adenocarcinomas with mucin were histologi-
cally predominant in approximately 10% cases. Patients 
with these tumors must be carefully evaluated before decid-
ing whether limited resection or omission of lymph node 
dissection is indicated.
A limitation of this study is its retrospective nature. 
Because the C/T ratio is a subjective parameter, more objec-
tive and quantitative parameters of these nodules are sought. 
Further research is necessary to achieve good inter- and 
intraobserver reproducibility of C/T ratio. de Hoop et al.23 
reported mass value, which was calculated by multiplying 
nodule volume by mean nodule density on TSCT as an objec-
tive measurement. In the future, innovative developments in 
imaging technology may enable accurate diagnosis of less-
invasive lung cancer comparable with pathological evaluation.
In conclusion, the C/T ratio of 0.5 or less identified early 
lung adenocarcinoma in patients with clinical T1bN0M0 dis-
ease. None of these tumors were solid adenocarcinoma pre-
dominant. The patients with these tumors had no lymph node 
involvement and developed no recurrence. These findings 
warrant a feasibility study of sublobar resection or reduction 
of the extent of mediastinal lymph node dissection for this 
population.
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